English
简体中文
Total: £ 56.28
Published Date: 2024-12-06 | Pages: 102 | Tables: 207 | Pharma & Healthcare
The global market for Psoriasis Biologics Drugs was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Psoriasis Biologics Drugs, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Psoriasis Biologics Drugs by region & country, by Type, and by Application.
The Psoriasis Biologics Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Psoriasis Biologics Drugs.
Market Segmentation
By Company
Amgen
UCB
Johnson & Johnson
Abbive
Innovent
Biocad
Novartis
Eli Lilly
Sun Pharmaceutical
Segment by Type:
TNF-α Inhibitor
IL-12/23 Target Drug
IL-17 Target Drug
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Psoriasis Biologics Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Psoriasis Biologics Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Psoriasis Biologics Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Market Overview
1.1 Psoriasis Biologics Drugs Product Introduction
1.2 Global Psoriasis Biologics Drugs Market Size Forecast
1.2.1 Global Psoriasis Biologics Drugs Sales Value (2019-2030)
1.2.2 Global Psoriasis Biologics Drugs Sales Volume (2019-2030)
1.2.3 Global Psoriasis Biologics Drugs Sales Price (2019-2030)
1.3 Psoriasis Biologics Drugs Market Trends & Drivers
1.3.1 Psoriasis Biologics Drugs Industry Trends
1.3.2 Psoriasis Biologics Drugs Market Drivers & Opportunity
1.3.3 Psoriasis Biologics Drugs Market Challenges
1.3.4 Psoriasis Biologics Drugs Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Psoriasis Biologics Drugs Players Revenue Ranking (2023)
2.2 Global Psoriasis Biologics Drugs Revenue by Company (2019-2024)
2.3 Global Psoriasis Biologics Drugs Players Sales Volume Ranking (2023)
2.4 Global Psoriasis Biologics Drugs Sales Volume by Company Players (2019-2024)
2.5 Global Psoriasis Biologics Drugs Average Price by Company (2019-2024)
2.6 Key Manufacturers Psoriasis Biologics Drugs Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Psoriasis Biologics Drugs Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Psoriasis Biologics Drugs
2.9 Psoriasis Biologics Drugs Market Competitive Analysis
2.9.1 Psoriasis Biologics Drugs Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Psoriasis Biologics Drugs Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Psoriasis Biologics Drugs as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 TNF-α Inhibitor
3.1.2 IL-12/23 Target Drug
3.1.3 IL-17 Target Drug
3.2 Global Psoriasis Biologics Drugs Sales Value by Type
3.2.1 Global Psoriasis Biologics Drugs Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Psoriasis Biologics Drugs Sales Value, by Type (2019-2030)
3.2.3 Global Psoriasis Biologics Drugs Sales Value, by Type (%) (2019-2030)
3.3 Global Psoriasis Biologics Drugs Sales Volume by Type
3.3.1 Global Psoriasis Biologics Drugs Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Psoriasis Biologics Drugs Sales Volume, by Type (2019-2030)
3.3.3 Global Psoriasis Biologics Drugs Sales Volume, by Type (%) (2019-2030)
3.4 Global Psoriasis Biologics Drugs Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital Pharmacies
4.1.2 Retail Pharmacies
4.1.3 Online Pharmacies
4.2 Global Psoriasis Biologics Drugs Sales Value by Application
4.2.1 Global Psoriasis Biologics Drugs Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Psoriasis Biologics Drugs Sales Value, by Application (2019-2030)
4.2.3 Global Psoriasis Biologics Drugs Sales Value, by Application (%) (2019-2030)
4.3 Global Psoriasis Biologics Drugs Sales Volume by Application
4.3.1 Global Psoriasis Biologics Drugs Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Psoriasis Biologics Drugs Sales Volume, by Application (2019-2030)
4.3.3 Global Psoriasis Biologics Drugs Sales Volume, by Application (%) (2019-2030)
4.4 Global Psoriasis Biologics Drugs Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Psoriasis Biologics Drugs Sales Value by Region
5.1.1 Global Psoriasis Biologics Drugs Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Psoriasis Biologics Drugs Sales Value by Region (2019-2024)
5.1.3 Global Psoriasis Biologics Drugs Sales Value by Region (2025-2030)
5.1.4 Global Psoriasis Biologics Drugs Sales Value by Region (%), (2019-2030)
5.2 Global Psoriasis Biologics Drugs Sales Volume by Region
5.2.1 Global Psoriasis Biologics Drugs Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Psoriasis Biologics Drugs Sales Volume by Region (2019-2024)
5.2.3 Global Psoriasis Biologics Drugs Sales Volume by Region (2025-2030)
5.2.4 Global Psoriasis Biologics Drugs Sales Volume by Region (%), (2019-2030)
5.3 Global Psoriasis Biologics Drugs Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Psoriasis Biologics Drugs Sales Value, 2019-2030
5.4.2 North America Psoriasis Biologics Drugs Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Psoriasis Biologics Drugs Sales Value, 2019-2030
5.5.2 Europe Psoriasis Biologics Drugs Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Psoriasis Biologics Drugs Sales Value, 2019-2030
5.6.2 Asia Pacific Psoriasis Biologics Drugs Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Psoriasis Biologics Drugs Sales Value, 2019-2030
5.7.2 South America Psoriasis Biologics Drugs Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Psoriasis Biologics Drugs Sales Value, 2019-2030
5.8.2 Middle East & Africa Psoriasis Biologics Drugs Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Psoriasis Biologics Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Psoriasis Biologics Drugs Sales Value
6.2.1 Key Countries/Regions Psoriasis Biologics Drugs Sales Value, 2019-2030
6.2.2 Key Countries/Regions Psoriasis Biologics Drugs Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Psoriasis Biologics Drugs Sales Value, 2019-2030
6.3.2 United States Psoriasis Biologics Drugs Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Psoriasis Biologics Drugs Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Psoriasis Biologics Drugs Sales Value, 2019-2030
6.4.2 Europe Psoriasis Biologics Drugs Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Psoriasis Biologics Drugs Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Psoriasis Biologics Drugs Sales Value, 2019-2030
6.5.2 China Psoriasis Biologics Drugs Sales Value by Type (%), 2023 VS 2030
6.5.3 China Psoriasis Biologics Drugs Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Psoriasis Biologics Drugs Sales Value, 2019-2030
6.6.2 Japan Psoriasis Biologics Drugs Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Psoriasis Biologics Drugs Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Psoriasis Biologics Drugs Sales Value, 2019-2030
6.7.2 South Korea Psoriasis Biologics Drugs Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Psoriasis Biologics Drugs Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Psoriasis Biologics Drugs Sales Value, 2019-2030
6.8.2 Southeast Asia Psoriasis Biologics Drugs Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Psoriasis Biologics Drugs Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Psoriasis Biologics Drugs Sales Value, 2019-2030
6.9.2 India Psoriasis Biologics Drugs Sales Value by Type (%), 2023 VS 2030
6.9.3 India Psoriasis Biologics Drugs Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Amgen
7.1.1 Amgen Company Information
7.1.2 Amgen Introduction and Business Overview
7.1.3 Amgen Psoriasis Biologics Drugs Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Amgen Psoriasis Biologics Drugs Product Offerings
7.1.5 Amgen Recent Development
7.2 UCB
7.2.1 UCB Company Information
7.2.2 UCB Introduction and Business Overview
7.2.3 UCB Psoriasis Biologics Drugs Sales, Revenue and Gross Margin (2019-2024)
7.2.4 UCB Psoriasis Biologics Drugs Product Offerings
7.2.5 UCB Recent Development
7.3 Johnson & Johnson
7.3.1 Johnson & Johnson Company Information
7.3.2 Johnson & Johnson Introduction and Business Overview
7.3.3 Johnson & Johnson Psoriasis Biologics Drugs Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Johnson & Johnson Psoriasis Biologics Drugs Product Offerings
7.3.5 Johnson & Johnson Recent Development
7.4 Abbive
7.4.1 Abbive Company Information
7.4.2 Abbive Introduction and Business Overview
7.4.3 Abbive Psoriasis Biologics Drugs Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Abbive Psoriasis Biologics Drugs Product Offerings
7.4.5 Abbive Recent Development
7.5 Innovent
7.5.1 Innovent Company Information
7.5.2 Innovent Introduction and Business Overview
7.5.3 Innovent Psoriasis Biologics Drugs Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Innovent Psoriasis Biologics Drugs Product Offerings
7.5.5 Innovent Recent Development
7.6 Biocad
7.6.1 Biocad Company Information
7.6.2 Biocad Introduction and Business Overview
7.6.3 Biocad Psoriasis Biologics Drugs Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Biocad Psoriasis Biologics Drugs Product Offerings
7.6.5 Biocad Recent Development
7.7 Novartis
7.7.1 Novartis Company Information
7.7.2 Novartis Introduction and Business Overview
7.7.3 Novartis Psoriasis Biologics Drugs Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Novartis Psoriasis Biologics Drugs Product Offerings
7.7.5 Novartis Recent Development
7.8 Eli Lilly
7.8.1 Eli Lilly Company Information
7.8.2 Eli Lilly Introduction and Business Overview
7.8.3 Eli Lilly Psoriasis Biologics Drugs Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Eli Lilly Psoriasis Biologics Drugs Product Offerings
7.8.5 Eli Lilly Recent Development
7.9 Sun Pharmaceutical
7.9.1 Sun Pharmaceutical Company Information
7.9.2 Sun Pharmaceutical Introduction and Business Overview
7.9.3 Sun Pharmaceutical Psoriasis Biologics Drugs Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Sun Pharmaceutical Psoriasis Biologics Drugs Product Offerings
7.9.5 Sun Pharmaceutical Recent Development
8 Industry Chain Analysis
8.1 Psoriasis Biologics Drugs Industrial Chain
8.2 Psoriasis Biologics Drugs Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Psoriasis Biologics Drugs Sales Model
8.5.2 Sales Channel
8.5.3 Psoriasis Biologics Drugs Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Psoriasis Biologics Drugs Market Trends
Table 2. Psoriasis Biologics Drugs Market Drivers & Opportunity
Table 3. Psoriasis Biologics Drugs Market Challenges
Table 4. Psoriasis Biologics Drugs Market Restraints
Table 5. Global Psoriasis Biologics Drugs Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Psoriasis Biologics Drugs Revenue Market Share by Company (2019-2024)
Table 7. Global Psoriasis Biologics Drugs Sales Volume by Company (2019-2024) & (K Units)
Table 8. Global Psoriasis Biologics Drugs Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market Psoriasis Biologics Drugs Price by Company (2019-2024) & (US$/Unit)
Table 10. Key Manufacturers Psoriasis Biologics Drugs Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers Psoriasis Biologics Drugs Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Psoriasis Biologics Drugs
Table 13. Global Psoriasis Biologics Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Psoriasis Biologics Drugs as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Psoriasis Biologics Drugs Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Psoriasis Biologics Drugs Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Psoriasis Biologics Drugs Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Psoriasis Biologics Drugs Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global Psoriasis Biologics Drugs Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global Psoriasis Biologics Drugs Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
Table 22. Global Psoriasis Biologics Drugs Sales Volume by Type (2019-2024) & (K Units)
Table 23. Global Psoriasis Biologics Drugs Sales Volume by Type (2025-2030) & (K Units)
Table 24. Global Psoriasis Biologics Drugs Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global Psoriasis Biologics Drugs Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global Psoriasis Biologics Drugs Price by Type (2019-2024) & (US$/Unit)
Table 27. Global Psoriasis Biologics Drugs Price by Type (2025-2030) & (US$/Unit)
Table 28. Global Psoriasis Biologics Drugs Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Psoriasis Biologics Drugs Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global Psoriasis Biologics Drugs Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global Psoriasis Biologics Drugs Sales Market Share in Value by Application (2019-2024) & (%)
Table 32. Global Psoriasis Biologics Drugs Sales Market Share in Value by Application (2025-2030) & (%)
Table 33. Global Psoriasis Biologics Drugs Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
Table 34. Global Psoriasis Biologics Drugs Sales Volume by Application (2019-2024) & (K Units)
Table 35. Global Psoriasis Biologics Drugs Sales Volume by Application (2025-2030) & (K Units)
Table 36. Global Psoriasis Biologics Drugs Sales Market Share in Volume by Application (2019-2024) & (%)
Table 37. Global Psoriasis Biologics Drugs Sales Market Share in Volume by Application (2025-2030) & (%)
Table 38. Global Psoriasis Biologics Drugs Price by Application (2019-2024) & (US$/Unit)
Table 39. Global Psoriasis Biologics Drugs Price by Application (2025-2030) & (US$/Unit)
Table 40. Global Psoriasis Biologics Drugs Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Psoriasis Biologics Drugs Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global Psoriasis Biologics Drugs Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global Psoriasis Biologics Drugs Sales Value by Region (2019-2024) & (%)
Table 44. Global Psoriasis Biologics Drugs Sales Value by Region (2025-2030) & (%)
Table 45. Global Psoriasis Biologics Drugs Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
Table 46. Global Psoriasis Biologics Drugs Sales Volume by Region (2019-2024) & (K Units)
Table 47. Global Psoriasis Biologics Drugs Sales Volume by Region (2025-2030) & (K Units)
Table 48. Global Psoriasis Biologics Drugs Sales Volume by Region (2019-2024) & (%)
Table 49. Global Psoriasis Biologics Drugs Sales Volume by Region (2025-2030) & (%)
Table 50. Global Psoriasis Biologics Drugs Average Price by Region (2019-2024) & (US$/Unit)
Table 51. Global Psoriasis Biologics Drugs Average Price by Region (2025-2030) & (US$/Unit)
Table 52. Key Countries/Regions Psoriasis Biologics Drugs Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions Psoriasis Biologics Drugs Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions Psoriasis Biologics Drugs Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions Psoriasis Biologics Drugs Sales Volume, (2019-2024) & (K Units)
Table 56. Key Countries/Regions Psoriasis Biologics Drugs Sales Volume, (2025-2030) & (K Units)
Table 57. Amgen Company Information
Table 58. Amgen Introduction and Business Overview
Table 59. Amgen Psoriasis Biologics Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 60. Amgen Psoriasis Biologics Drugs Product Offerings
Table 61. Amgen Recent Development
Table 62. UCB Company Information
Table 63. UCB Introduction and Business Overview
Table 64. UCB Psoriasis Biologics Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 65. UCB Psoriasis Biologics Drugs Product Offerings
Table 66. UCB Recent Development
Table 67. Johnson & Johnson Company Information
Table 68. Johnson & Johnson Introduction and Business Overview
Table 69. Johnson & Johnson Psoriasis Biologics Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 70. Johnson & Johnson Psoriasis Biologics Drugs Product Offerings
Table 71. Johnson & Johnson Recent Development
Table 72. Abbive Company Information
Table 73. Abbive Introduction and Business Overview
Table 74. Abbive Psoriasis Biologics Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 75. Abbive Psoriasis Biologics Drugs Product Offerings
Table 76. Abbive Recent Development
Table 77. Innovent Company Information
Table 78. Innovent Introduction and Business Overview
Table 79. Innovent Psoriasis Biologics Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 80. Innovent Psoriasis Biologics Drugs Product Offerings
Table 81. Innovent Recent Development
Table 82. Biocad Company Information
Table 83. Biocad Introduction and Business Overview
Table 84. Biocad Psoriasis Biologics Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 85. Biocad Psoriasis Biologics Drugs Product Offerings
Table 86. Biocad Recent Development
Table 87. Novartis Company Information
Table 88. Novartis Introduction and Business Overview
Table 89. Novartis Psoriasis Biologics Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 90. Novartis Psoriasis Biologics Drugs Product Offerings
Table 91. Novartis Recent Development
Table 92. Eli Lilly Company Information
Table 93. Eli Lilly Introduction and Business Overview
Table 94. Eli Lilly Psoriasis Biologics Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 95. Eli Lilly Psoriasis Biologics Drugs Product Offerings
Table 96. Eli Lilly Recent Development
Table 97. Sun Pharmaceutical Company Information
Table 98. Sun Pharmaceutical Introduction and Business Overview
Table 99. Sun Pharmaceutical Psoriasis Biologics Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 100. Sun Pharmaceutical Psoriasis Biologics Drugs Product Offerings
Table 101. Sun Pharmaceutical Recent Development
Table 102. Key Raw Materials Lists
Table 103. Raw Materials Key Suppliers Lists
Table 104. Psoriasis Biologics Drugs Downstream Customers
Table 105. Psoriasis Biologics Drugs Distributors List
Table 106. Research Programs/Design for This Report
Table 107. Key Data Information from Secondary Sources
Table 108. Key Data Information from Primary Sources
List of Figures
Figure 1. Psoriasis Biologics Drugs Product Picture
Figure 2. Global Psoriasis Biologics Drugs Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Psoriasis Biologics Drugs Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Psoriasis Biologics Drugs Sales Volume (2019-2030) & (K Units)
Figure 5. Global Psoriasis Biologics Drugs Sales Price (2019-2030) & (US$/Unit)
Figure 6. Psoriasis Biologics Drugs Report Years Considered
Figure 7. Global Psoriasis Biologics Drugs Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global Psoriasis Biologics Drugs Players Sales Volume Ranking (2023) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Psoriasis Biologics Drugs Revenue in 2023
Figure 10. Psoriasis Biologics Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. TNF-α Inhibitor Picture
Figure 12. IL-12/23 Target Drug Picture
Figure 13. IL-17 Target Drug Picture
Figure 14. Global Psoriasis Biologics Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 15. Global Psoriasis Biologics Drugs Sales Value Market Share by Type, 2023 & 2030
Figure 16. Global Psoriasis Biologics Drugs Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 17. Global Psoriasis Biologics Drugs Sales Volume Market Share by Type, 2023 & 2030
Figure 18. Global Psoriasis Biologics Drugs Price by Type (2019-2030) & (US$/Unit)
Figure 19. Product Picture of Hospital Pharmacies
Figure 20. Product Picture of Retail Pharmacies
Figure 21. Product Picture of Online Pharmacies
Figure 22. Global Psoriasis Biologics Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 23. Global Psoriasis Biologics Drugs Sales Value Market Share by Application, 2023 & 2030
Figure 24. Global Psoriasis Biologics Drugs Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 25. Global Psoriasis Biologics Drugs Sales Volume Market Share by Application, 2023 & 2030
Figure 26. Global Psoriasis Biologics Drugs Price by Application (2019-2030) & (US$/Unit)
Figure 27. North America Psoriasis Biologics Drugs Sales Value (2019-2030) & (US$ Million)
Figure 28. North America Psoriasis Biologics Drugs Sales Value by Country (%), 2023 VS 2030
Figure 29. Europe Psoriasis Biologics Drugs Sales Value (2019-2030) & (US$ Million)
Figure 30. Europe Psoriasis Biologics Drugs Sales Value by Country (%), 2023 VS 2030
Figure 31. Asia Pacific Psoriasis Biologics Drugs Sales Value (2019-2030) & (US$ Million)
Figure 32. Asia Pacific Psoriasis Biologics Drugs Sales Value by Country (%), 2023 VS 2030
Figure 33. South America Psoriasis Biologics Drugs Sales Value (2019-2030) & (US$ Million)
Figure 34. South America Psoriasis Biologics Drugs Sales Value by Country (%), 2023 VS 2030
Figure 35. Middle East & Africa Psoriasis Biologics Drugs Sales Value (2019-2030) & (US$ Million)
Figure 36. Middle East & Africa Psoriasis Biologics Drugs Sales Value by Country (%), 2023 VS 2030
Figure 37. Key Countries/Regions Psoriasis Biologics Drugs Sales Value (%), (2019-2030)
Figure 38. Key Countries/Regions Psoriasis Biologics Drugs Sales Volume (%), (2019-2030)
Figure 39. United States Psoriasis Biologics Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 40. United States Psoriasis Biologics Drugs Sales Value by Type (%), 2023 VS 2030
Figure 41. United States Psoriasis Biologics Drugs Sales Value by Application (%), 2023 VS 2030
Figure 42. Europe Psoriasis Biologics Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 43. Europe Psoriasis Biologics Drugs Sales Value by Type (%), 2023 VS 2030
Figure 44. Europe Psoriasis Biologics Drugs Sales Value by Application (%), 2023 VS 2030
Figure 45. China Psoriasis Biologics Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 46. China Psoriasis Biologics Drugs Sales Value by Type (%), 2023 VS 2030
Figure 47. China Psoriasis Biologics Drugs Sales Value by Application (%), 2023 VS 2030
Figure 48. Japan Psoriasis Biologics Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 49. Japan Psoriasis Biologics Drugs Sales Value by Type (%), 2023 VS 2030
Figure 50. Japan Psoriasis Biologics Drugs Sales Value by Application (%), 2023 VS 2030
Figure 51. South Korea Psoriasis Biologics Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 52. South Korea Psoriasis Biologics Drugs Sales Value by Type (%), 2023 VS 2030
Figure 53. South Korea Psoriasis Biologics Drugs Sales Value by Application (%), 2023 VS 2030
Figure 54. Southeast Asia Psoriasis Biologics Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 55. Southeast Asia Psoriasis Biologics Drugs Sales Value by Type (%), 2023 VS 2030
Figure 56. Southeast Asia Psoriasis Biologics Drugs Sales Value by Application (%), 2023 VS 2030
Figure 57. India Psoriasis Biologics Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 58. India Psoriasis Biologics Drugs Sales Value by Type (%), 2023 VS 2030
Figure 59. India Psoriasis Biologics Drugs Sales Value by Application (%), 2023 VS 2030
Figure 60. Psoriasis Biologics Drugs Industrial Chain
Figure 61. Psoriasis Biologics Drugs Manufacturing Cost Structure
Figure 62. Channels of Distribution (Direct Sales, and Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
